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Background:  TAK-442 is an oral, direct factor Xa inhibitor under development for the secondary prevention of atherothrombotic events. Prasugrel, 
a thienopyridine oral antiplatelet agent, is indicated for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome. 
Patients who may benefit from TAK-442 are likely to receive concomitant administration of antiplatelet agents such as prasugrel. This study was 
therefore conducted to evaluate the potential pharmacodynamic (PD) interaction between TAK-442 and prasugrel.
Methods:  In this randomized, single-blind, placebo-controlled, multiple-dose, 2-way crossover study, 22 healthy subjects received; A: Prasugrel 
60 mg loading dose on Day 1 followed by 10 mg once daily (QD) on days 2-14, + placebo twice daily (BID) on days 8-14 or B: Prasugrel 60 mg 
loading dose on Day 1 followed by 10 mg QD on days 2-14 + TAK-442 60 mg BID on days 8-14. There was a minimum 21 day washout between 
treatments. Blood samples to determine inhibition of ADP-induced platelet aggregation, at 20 and 30 μM ADP, were collected 2 h post dose on day 
14. Prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), and bleeding time were assessed at 
regular intervals throughout the study.
Results:  Prasugrel inhibited 20 and 30 μM ADP-induced platelet aggregation by 87.3% and 88.4%, respectively at 2 h postdose on Day 14. Similar 
inhibition was observed when TAK-442 was coadministered with prasugrel (88.4% at 20μM ADP; 86.3% at 30μM). Mean INR at 2 h postdose on day 
14 was 1.876 during administration of TAK-442 + prasugrel, compared to 1.030 during administration of prasugrel + placebo. Mean PT and aPTT 
increased from 13.9 and 34.3 seconds, respectively, during administration of prasugrel + placebo to 22.6 and 45.5 seconds, respectively during 
administration of TAK-442 + prasugrel.
Conclusions:  Administration of TAK-442 + prasugrel in healthy volunteers did not result in greater ADP induced platelet aggregation than prasugrel 
alone, however coadministration increased aPTT, PT, and INR compared to prasugrel alone.
